Cargando…

Non-melanoma Skin Cancers in Patients on Hydroxyurea for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review

Hydroxyurea (HU) or hydroxycarbamide is a cytotoxic antimetabolite widely used to treat Philadelphia chromosome-negative Myeloproliferative Neoplasms (Ph-MPN) like Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF). Patients with Ph-MPN are at an increased risk o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gavini, Divya R, Salvi, Dhairya J, Shah, Prutha H, Uma, Davuluri, Lee, Jun Hee, Hamid, Pousette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Dermatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420994/ https://www.ncbi.nlm.nih.gov/pubmed/34527458 http://dx.doi.org/10.7759/cureus.16978

Ejemplares similares

Testosterone Replacement Therapy in Hypogonadal Men and Myocardial Infarction Risk: Systematic Review & Meta-Analysis
por: Lee, Jun Hee, et al.
Publicado: (2021)

Cardiovascular System Involvement in Cystic Fibrosis
por: Shah, Prutha H, et al.
Publicado: (2021)

Does Hormone Supplementation With Levothyroxine Improve Hypothyroid Impaired Cognitive Dysfunction?
por: Uma, Davuluri, et al.
Publicado: (2021)

The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
por: Kiem, Dominik, et al.
Publicado: (2021)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
por: Campregher, Paulo Vidal, et al.
Publicado: (2012)

Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms()
por: Pagnano, Katia Borgia Barbosa
Publicado: (2018)

Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
por: Cominal, Juçara Gastaldi, et al.
Publicado: (2021)

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms
por: Ipek, Yonal-Hindilerden, et al.
Publicado: (2017)

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Liisborg, Charlotte, et al.
Publicado: (2020)

Philadelphia‐negative myeloproliferative neoplasms among Kuwaiti Nationals
por: Alshemmari, Salem, et al.
Publicado: (2020)

Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms
por: Lee, Myung-Won, et al.
Publicado: (2022)

Applications of Artificial Intelligence in Philadelphia-Negative Myeloproliferative Neoplasms
por: Elsayed, Basel, et al.
Publicado: (2023)

Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Philadelphia, Pennsylvania, USA
por: Malayala, Srikrishna V, et al.
Publicado: (2022)

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
por: Kaplan, Jason B., et al.
Publicado: (2016)

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
por: Cacemiro, Maira da Costa, et al.
Publicado: (2018)

Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic
por: Barbui, Tiziano, et al.
Publicado: (2021)

The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms
por: Lanzarone, Giuseppe, et al.
Publicado: (2021)

The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
por: Yoon, Seug Yun, et al.
Publicado: (2021)

Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms
por: Stuckey, Ruth, et al.
Publicado: (2023)

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
por: Wang, Rong, et al.
Publicado: (2022)

The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
por: Wu, Zhiyuan, et al.
Publicado: (2014)

Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review
por: Malato, Alessandra, et al.
Publicado: (2020)

Erratum on “Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation”
por: Cacemiro, Maira da Costa, et al.
Publicado: (2021)

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
por: Mora, Barbara, et al.
Publicado: (2022)

The Genomic Landscape in Philadelphia-Negative Myeloproliferative Neoplasm Patients with Second Cancers
por: Hsu, Chia-Chen, et al.
Publicado: (2022)

Acquired von willebrand syndrome in patients with Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2023)

A Case of Philadelphia Chromosome Positive Myeloproliferative Neoplasm in a Pregnant Woman with Unusual Primary Myelofibrosis Features
por: Koshy, Jason, et al.
Publicado: (2013)

CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome–negative myeloproliferative neoplasms
por: Morishita, Soji, et al.
Publicado: (2020)

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
por: Yung, Yammy, et al.
Publicado: (2021)

Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?
por: Fulvio, Giovanni, et al.
Publicado: (2023)

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
por: Barbui, Tiziano, et al.
Publicado: (2018)

Treatment outcome of Philadelphia chromosome negative myeloproliferative neoplasms: experience of a single developing country's hematology-oncology centre
por: Salim, Mohammed, et al.
Publicado: (2019)

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms
por: Pandey, Ruchi, et al.
Publicado: (2015)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms
por: Benedetti, Edoardo, et al.
Publicado: (2020)

Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2022)

CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms
por: Hodeib, Hossam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t8dhssu8d9d50bmh38l88dr2hq